Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable.
作者信息
Adashi Eli Y, Gruppuso Philip A
机构信息
Department of Medical Science, The Warren Alpert Medical School, Brown University, Providence, Rhode Island.
Department of Pediatrics, The Warren Alpert Medical School, Brown University, Providence, Rhode Island; Molecular Biology, Cell Biology and Biochemistry, The Warren Alpert Medical School, Brown University, Providence, Rhode Island.
出版信息
Am J Prev Med. 2022 Dec;63(6):1062-1063. doi: 10.1016/j.amepre.2022.06.009. Epub 2022 Jul 11.
Abstract
摘要
相似文献
1
Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable.鼻内接种新冠病毒疫苗：不可或缺且势在必行。
Am J Prev Med. 2022 Dec;63(6):1062-1063. doi: 10.1016/j.amepre.2022.06.009. Epub 2022 Jul 11.
2
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
3
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.鼻内给予一剂基于 MVA 的 COVID-19 候选疫苗可诱导局部和全身免疫应答，并可保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Sep 12;13:995235. doi: 10.3389/fimmu.2022.995235. eCollection 2022.
4
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
5
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.鼻腔接种基于 MVA 的疫苗可诱导 IgA 并保护 hACE2 小鼠的呼吸道免受 SARS-CoV-2 感染。
Proc Natl Acad Sci U S A. 2022 Jun 14;119(24):e2202069119. doi: 10.1073/pnas.2202069119. Epub 2022 Jun 9.
6
SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies.新冠病毒（SARS-CoV-2）感染发生在完全接种疫苗很长时间后，与中和抗体缺乏有关。
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115565. doi: 10.1016/j.diagmicrobio.2021.115565. Epub 2021 Oct 2.
7
Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone.与单独接种疫苗相比，感染 SARS-CoV-2 后接种疫苗可提高针对奥密克戎变异株的抗体亲合力。
J Infect Dis. 2022 Nov 11;226(10):1712-1716. doi: 10.1093/infdis/jiac247.
8
Billions boost next-generation weapons against SARS-CoV-2.数十亿美元推动针对 SARS-CoV-2 的下一代武器研发。
Science. 2023 Oct 27;382(6669):359-360. doi: 10.1126/science.adl5523. Epub 2023 Oct 26.
9
Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.法国开展疫苗接种 6 个月后，初级保健工作者中 SARS-CoV-2 IgG 抗体的血清阳性率及其与 SARS-CoV-2 IgG 中和活性相关的因素。
Viruses. 2022 May 3;14(5):957. doi: 10.3390/v14050957.
10
Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的体液免疫和适应性免疫反应。
Int J Infect Dis. 2022 Sep;122:412-414. doi: 10.1016/j.ijid.2022.06.020. Epub 2022 Jun 21.
引用本文的文献
1
Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.基于纳米技术的气道炎症性疾病治疗方法
Clin Rev Allergy Immunol. 2025 Feb 10;68(1):12. doi: 10.1007/s12016-024-09019-w.
2
Insights for COVID-19 in 2023.2023 年对 COVID-19 的洞察。
Rev Esp Quimioter. 2023 Apr;36(2):114-124. doi: 10.37201/req/122.2022. Epub 2022 Dec 13.
Zotero 插件